E
CGEM icon

Ergoteles’s Cullinan Oncology CGEM Stock Holding History

Ergoteles’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-48,622
Closed -$497K – 1097
2023
Q1 		$497K Buy
+48,622
New +$536K 0.02% 734

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ergoteles's CGEM Position: Q2 2023 in Review

Ergoteles sold out of Cullinan Oncology (CGEM) in Q2 2023, closing a stake of 48,622 shares — an estimated $497K sold.

Ergoteles first reported a position in CGEM in Q1 2023 and held it in 1 quarter. The position peaked at $497K in Q1 2023. 106 funds tracked by Wall St. Rank hold CGEM as of Q2 2023.

  • Ergoteles reported no remaining Cullinan Oncology position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 48,622 Cullinan Oncology shares in Q2 2023, an estimated $497K.
  • Ergoteles first reported a position in Cullinan Oncology in Q1 2023 and held it in 1 quarter.
  • Ergoteles's Cullinan Oncology position peaked at $497K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.